fbpx
Connect with us

Hi, what are you looking for?

UpNow Media

Finance

Moderna coronavirus vaccine’s 1st results are promising, but it’s still too early to be a winner

Moderna coronavirus vaccine reports encouraging interim results from ongoing Phase 1 trials, a potential to produce immunity in people.

Moderna coronavirus vaccine is showing promising results.

If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates.

Drug maker Moderna has just announced encouraging interim results from the ongoing phase 1 trial for its experimental coronavirus vaccine. The early results suggest the vaccine has the potential to confer immunity against covid-19 in people.

What is Moderna coronavirus vaccine and how does it work?

Moderna specializes in vaccines designed to elicit an immune response against the coronavirus through the virus’s mRNA—genetic instructions for the virus to replicate inside the host. New methods like Moderna’s are fast to prepare, but they have never led to a licensed vaccine for sale.

Phase 1 trials

Moderna coronavirus vaccine has promising results with Phase 1 trials.
Moderna has announced promising results with Phase 1 trials.

The purpose of a phase 1 clinical trial is to establish whether or not the drug or vaccine being investigated is safe. It’s not designed to test for efficacy. That being said, the trials can still provide some insights into the potential of the drug or vaccine to treat patients. Moderna’s trial, which began in March and is still ongoing, is set to enroll up to 105 people. Each participant receives either two shots at 25 micrograms or 100 micrograms (about four weeks apart) or a single dose at 250 micrograms. 

The new results

Moderna released antibody data for eight participants (aged 18 to 55), four in the 25-microgram arm and four in the 100-microgram arm. The results, according to the company, show that 25-microgram participants developed neutralizing antibodies to the coronavirus at levels comparable to recovered covid-19 patients; those in the 100-microgram arm had antibody levels that “significantly exceeded” the level in recovered patients. Adverse effects have been observed, but the company’s statement insists they “have been transient and self-resolving.” 

Next steps

The results are encouraging, but we can’t draw conclusions from a phase 1 trial, with data from only eight participants so far. Way more data is needed. The FDA has already given Moderna approval for a phase 2 trial (testing the drug’s biological effect on patients), and Moderna says it will add a 50-microgram arm to the phase 2 study. A phase 3 trial is expected to start in July. According to the Wall Street Journal, if all Moderna’s trials go well—and that’s a big if—the FDA could grant emergency-use authorization for the vaccine by the fall.

Other companies with potential vaccines

Another U.S. biotech company, Novavax, is starting trials for its vaccine candidate and is confident of producing 100m doses by end of 2020.

Japanese biotech company, Takara Bio Inc is also commencing trials with production facilities ready. Takara partnered with bio company AnGes and Osaka University to develop the DNA COVID-19 vaccine.

If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates.

Related Articles

Worldwide

Post Views: 86 If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates. About 90 per...

Politics

Post Views: 20 If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates. Obama rips Trump,...

Fashion

Post Views: 24 If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates. Hear from Carla...

Worldwide

Post Views: 37 If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates. Jon Gwyther shot...

Advertisement
Advertisement
Advertisement
Advertisement